Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-769-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.17 million
Profitability
Miscellaneous
Employees80
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) posted its earnings results on Thursday, November, 7th. The medical instruments supplier reported $0.27 EPS for the quarter. The medical instruments supplier earned $7.24 million during the quarter. Pro-Dex had a net margin of 14.19% and a return on equity of 22.60%. View Pro-Dex's Earnings History.
When is Pro-Dex's next earnings date?
What price target have analysts set for PDEX?
1 Wall Street analysts have issued twelve-month target prices for Pro-Dex's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Pro-Dex's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Price Targets for Pro-Dex.
What is the consensus analysts' recommendation for Pro-Dex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pro-Dex.
Has Pro-Dex been receiving favorable news coverage?
Press coverage about PDEX stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pro-Dex earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Pro-Dex.
Are investors shorting Pro-Dex?
Pro-Dex saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 9,800 shares, a decline of 20.3% from the December 15th total of 12,300 shares. Based on an average daily volume of 15,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.4% of the shares of the stock are sold short. View Pro-Dex's Current Options Chain.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include RenovaCare (RCAR), Soliton (SOLY), Vapotherm (VAPO), Repro-Med Systems (REPR), Repro Med Systems (KRMD), Restoration Robotics (HAIR), TELA Bio (TELA), iCAD (ICAD), Venus Concept (VERO), Cytosorbents (CTSO), Liquidia Technologies (LQDA), BRAINSWAY LTD/S (BWAY), Spectral Medical (EDTXF), BeyondAirInc . (XAIR) and Neuronetics (STIM).
What other stocks do shareholders of Pro-Dex own?
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
Who are Pro-Dex's major shareholders?
Pro-Dex's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.29%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View Institutional Ownership Trends for Pro-Dex.
Which institutional investors are selling Pro-Dex stock?
PDEX stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, David Hovda and Raymond E Cabillot. View Insider Buying and Selling for Pro-Dex.
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $16.78.
How big of a company is Pro-Dex?
What is Pro-Dex's official website?
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
